Alpha Tau Medical Ltd

NASDAQ DRTS

Data sourced from

and

Download Data

Alpha Tau Medical Ltd Non-current Assets to Total Assets Ratio for the year ending December 31, 2023: 0.20

Alpha Tau Medical Ltd Non-current Assets to Total Assets Ratio is 0.20 for the year ending December 31, 2023, a 77.02% change year over year. The non-current assets to total assets ratio measures the proportion of a company's non-current assets to its total assets. It is calculated by dividing the total non-current assets by the total assets. This ratio provides insights into the composition of a company's asset base and the extent to which it relies on non-current assets, such as property, plant, and equipment, to generate revenue. A higher ratio suggests a greater proportion of non-current assets, indicating potential long-term stability and investment in fixed assets.

Alpha Tau Medical Ltd Non-current Assets to Total Assets Ratio for the year ending December 31, 2022 was 0.11, a -49.83% change year over year.
Alpha Tau Medical Ltd Non-current Assets to Total Assets Ratio for the year ending December 31, 2021 was 0.23, a 117.16% change year over year.
Alpha Tau Medical Ltd Non-current Assets to Total Assets Ratio for the year ending December 31, 2020 was 0.10, a 90.50% change year over year.
Alpha Tau Medical Ltd Non-current Assets to Total Assets Ratio for the year ending December 31, 2019 was 0.05.

NASDAQ: DRTS

Alpha Tau Medical Ltd

CEO	Mr. Uzi Sofer
IPO Date	March 8, 2021
Location	Israel
Headquarters	5 Kiryat Hamada Street, Jerusalem, Israel, 9777605
Employees	121
Sector	Healthcare
Industry	Biotechnology

Description

Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. The company's Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; preclinical or pending clinical studies for brain and other cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. Alpha Tau Medical Ltd. was incorporated in 2015 and is headquartered in Jerusalem, Israel.

Key trends